Newswire (Published: Friday, March 17, 2017, 12:01:00 AM CDT, Received: Thursday, March 9, 2017, 7:31:11 PM CST)

Word Count: 483

Study Results from G. Facchini and Colleagues Update Understanding of Prostate Cancer (Optimal Management of Prostate Cancer Based on its Natural Clinical History)

By a News Reporter-Staff News Editor at Drug Week -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting originating in Naples, Italy, by NewsRx journalists, research stated, "Prostate cancer is the most common malignancy in males and, despite a marked improvement in diagnostic techniques, a not small percentage of prostate tumours is still diagnosed in advanced stage. It is now clear that prostate cancer passes through distinct phases during its natural history, starting from an initial phase, in which the disease has a locoregional extent, until a very late phase when it becomes refractory to hormone therapy."

The news reporters obtained a quote from the research, "It is important to distinguish between local disease, in which tumor may be considered localized in the gland and a systemic disease characterized by high tumor burden and/or dissemination of circulating tumor cells. All the prostate cancers, at first diagnosis, are characterized by high sensitivity to the androgen deprivation therapy (ADT); however, during the natural history, after a variable period, they become castration resistant. In the past, few therapy options were available for castration resistant prostate cancer, while at present much more approaches can be employed, both hormone-based therapies and chemotherapy regimens. Hypercastration agents are defined as drugs capable to target the androgen-androgen receptor axis even in castrate resistant conditions. Abiraterone and enzalutamide are the only two hypercastration agents available for clinical use. Osteoclast targeted agents, such as zoledronic acid and denosumab can always been employed, but their use should be limited to the castrate resistant setting."

According to the news reporters, the research concluded: "The optimal understanding of all phases characterizing the natural history of prostate cancer may certainly be useful for the selection of the best therapeutic options in prostate cancer."

For more information on this research see: Optimal Management of Prostate Cancer Based on its Natural Clinical History. Current Cancer Drug Targets, 2017;():. (Bentham Science Publishers - www.benthamscience.com; Current Cancer Drug Targets - www.benthamscience.com/ccdt/index.htm)

Our news correspondents report that additional information may be obtained by contacting G. Facchini, Division of Medical Oncology, Dept. of Uro-Gynaecological Oncology, Istituto Nazionale Tumori Fondazione G Pascale - IRCCS, Via Mariano Semmola, 80131 Naples, Italy. Additional authors for this research include F. Perri, G. Misso, C. D Aniello, G.D. Scarpati, S. Rossetti, C.D. Pepa, S. Pisconti, G. Unteregger, A. Cossu, M. Caraglia, M. Berretta and C. Cavaliere (see also Oncology - Prostate Cancer).

Keywords for this news article include: Italy, Naples, Europe, Hormones, Oncology, Androgens, Prostate Cancer, Drugs and Therapies, Prostatic Neoplasms.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Southern Europe
Italy
Europe
Napoli

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies